NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Receives USFDA Establishment Inspection Report with Voluntary Action Indicated for Visakhapatnam Facility

This is to inform you that the Company has received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) from the U.S. Food and Drug Administration (USFDA), for our API facility (Site 5), located at Visakhapatnam, Andhra Pradesh.

This is based on a GMP inspection conducted by the agency between the 17th and 21st of June, 2024

Biocon remains committed to Quality, Safety & Efficacy of the products manufactured.